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Hepatitis B x antigen up-regulates the liver expression of URG7 that contributes to sustain chronic
virus infection and to increase the risk for hepatocellular carcinoma by its anti-apoptotic activity.
We have investigated the subcellular localization of URG7 expressed in HepG2 cells and determined
its membrane topology by glycosylation mapping in vitro. The results demonstrate that URG7 is
N-glycosylated and located to the endoplasmic reticulum membrane with an Nlumen–Ccytosol orienta-
tion. The results imply that the anti-apoptotic effect of URG7 could arise from the C-terminal
cytosolic tail binding a pro-apoptotic signaling factor and retaining it to the endoplasmic reticulum
membrane.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Approximately two billion people worldwide have been in-
fected with hepatitis B virus (HBV) and the consequences of acute
and chronic infections can lead to chronic liver disease, cirrhosis
and cancer, which cause 600000 deaths every year [1]. An impor-
tant factor encoded by the virus, HBV x antigen, acts by up- and
down-regulating host gene expression and thereby it induces a
number of cellular responses that are involved in the pathogenesis
of chronic infection and the development of hepatocellular carci-
noma (HCC). One of the genes whose expression is induced by
HBV x antigen in hepatocytes infected by HBV is the up-regulated
gene clone 7 (URG7) encoding the protein URG7 [2]. It has been re-
ported that URG7 inhibits TNFa-mediated apoptosis through
blocking one or more caspases, probably by activating anti-apopto-
tic signaling through phosphoinositol-3-kinase and b-catenin [3].
Antibodies against URG7 are detected in the serum of HBV carriers
before the appearance of HCC. Therefore URG7 could be used as apreneoplastic marker to identify HBV carriers at risk of developing
HCC [4] and could represent a molecular target for anti-tumor
therapies.
Although URG7 has an important role in the HBV x antigen in-
duced cellular response, very little is known about it. URG7 con-
sists of 99 amino acids [2], of which the N-terminal 74 residues
are identical to the N-terminal of the multidrug-resistance protein
6 (MRP6/ABCC6), while the remaining 25 C-terminal residues are
unrelated. MRP6 is a member of the ATP binding cassette trans-
porter family in which mutations cause pseudoxanthoma elasti-
cum [5]. The similarity between URG7 and MRP6 can be
explained by URG7 being encoded by the so-called pseudogene 2
of ABCC6. The peptide sequence in common between the two pro-
teins contains one predicted transmembrane segment preceded by
an N-linked glycosylation site that has been shown to be glycosyl-
ated in MRP6 expressed in MDCKII cells [6]. In these polarized cells,
MRP6 is localized to the basolateral membrane exclusively but re-
cent studies have suggested that it is localized to mitochondria-
associated membranes [7]. However, the cellular localization of
URG7 is still unknown.
We have investigated the subcellular localization and topology
of URG7. Results obtained in HepG2 cells transfected with URG7
demonstrate that this protein is glycosylated and localized to the
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in vitro system conﬁrm its ER targeting and show that its only pre-
dicted transmembrane segment is integrated into the ER mem-
brane with an Nlumen–Ccytosol orientation. These ﬁndings suggest
that URG7 might act by anchoring a pro-apoptotic agent or signal
to the ER membrane and thereby have an anti-apoptotic effect.
2. Materials and methods
Detailed protocols for the methods can be found in Supplemen-
tary materials.
2.1. Construction of URG7 expression vector and transfection in HepG2
cells
Total RNA was isolated from human hepatoblastoma cell line
HepG2 and was transcribed to cDNA corresponding to the encod-
ing sequence for URG7 (GenBank AY078405) with a ﬂag tag
(DYKDDDDK) at the C-terminus. The ampliﬁed DNA was cloned
into pcDNA3 vector and the inserts were conﬁrmed by DNA
sequencing. HepG2 cells were grown in Dulbecco’s modiﬁed essen-
tial medium until 70% conﬂuent and then transfected with
pcDNA3/URG7ﬂag.
2.2. Immunoblotting, deglycosylation assay and tunicamycin
treatment
Proteins from RIPA lysed HepG2 cells transfected with empty
vector pcDNA3 and with pcDNA3/URG7ﬂag were resolved by
SDS–PAGE and transferred onto nitrocellulose membranes that
were used for Western blots with monoclonal Anti-Flag M2 and
HRP-coupled anti-mouse secondary antibodies. For the deglycosy-
lation assay, URG7ﬂag expressing cells were denaturated and trea-
ted with protease inhibitors and PNGase F. To inhibit the N-linked
glycosylation of proteins, transfected HepG2 cells were grown in
medium containing tunicamycin.
2.3. Immunoﬂuorescence
Forty-eight hours after transfection, the cells were ﬁxed,
washed and incubated with monoclonal Anti-FlagM2 antibody,
calnexin antibody or anti-TGN46 antibody. Bound antibodies were
detected with Alexa Fluor-conjugated anti-mouse, anti-goat and
anti-rabbit IgG antibody, respectively. To label mitochondria, cells
were incubated with MitoTracker Red CMXRos. Confocal images
were obtained with a laser scanning ﬂuorescence microscope Leica
TSC-SP2.
2.4. In vitro expression
The human URG7 and MRP6 (TM1–TM2) [8] genes were cloned
in the pGEM1 plasmid by themselves or as fusion proteins with the
P2 domain of Lep [9,10], similar to what has been describedBA
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Fig. 1. Immunoblot analysis. (A) HepG2 cells transfected with empty vector pcDNA3 (
Whole lysate from URG7ﬂag expressing cells was incubated in the presence or absence of
cells grown in the presence or absence (+/, respectively) of tunicamycin (5 lg/ml).
respectively.previously with other proteins [11] and with similar consider-
ations [9,12]. N-glycosylation acceptor sites were designed as de-
scribed [13,14]. To introduce additional glycosylation acceptor
sites into the URG7 gene near the N-terminal of the protein,
P7C8A9G10 was substituted to ANAT, and near the C-terminal, the
glycosylation site sequence NST was introduced between the posi-
tions K72–M73. The P2 domain of Lep had an additional glycosyla-
tion acceptor site N97S98T99 [10,15] in the wild type sequence of
Lep. All inserted fragments and mutants were conﬁrmed by
sequencing of plasmid DNA.
Constructs cloned in pGEM1 were transcribed and translated in
the TNT SP6 Quick Coupled System as previously described
[10,15] in the presence and absence of dog pancreas rough micro-
somes (CRMs) [16]. To demonstrate N-linked glycosylation by oli-
gosaccharyl transferase, Endo H treatment was performed as
described [10]. Translation products were analyzed by SDS–PAGE,
visualized in a Fuji FLA-300 phosphoimager and quantiﬁed with
the MultiGauge (Fujiﬁlm) software.
3. Results
3.1. Cellular localization of URG7 expressed in HepG2 cells
To investigate the subcellular localization of URG7, a C-terminal
ﬂagged URG7 construct was expressed in HepG2 cells. URG7 was
detected on immunoblots of cell lysates collected 48 h after trans-
fection, by using an anti-Flag tag antibody (Fig. 1A, lane 2). Two
URG7 protein bands migrated between the 7 and 17 kDa markers.
The size of the lower band ﬁts well with the predicted molecular
weight of the ﬂag-tagged URG7 protein (12 kDa), while the upper
band could correspond to a glycosylated form of URG7. This
hypothesis was tested by treating the cell lysate with the deglyco-
sylation enzyme PNGase F (Fig. 1B) and tunicamycin treatment of
the HepG2 cells (Fig. 1C), which both resulted in the disappearance
of the upper URG7 protein band, indicating that it corresponds to
an N-glycosylated form of URG7. Because the sequence of URG7
contains a single N-linked consensus glycosylation site,
N15Q16T17, located N-terminally of the predicted transmembrane
segment (residues 34–56 according to TMHMM [17]), we deduced
that this particular site is modiﬁed and that this fraction of 30–35%
of URG7 is targeted to the ER where N-glycosylation exclusively
takes place.
To investigate if URG7 is localized to the ER or continues
through the secretory pathway, URG7ﬂag in HepG2 cells was fol-
lowed by using immunoﬂuorescent microscopy. URG7 was found
around the nucleus and streaked out along the cellular body (green
signal), which coincided with the localization of the ER marker
calnexin (red signal, Fig. 2A). URG7 did not enter the Golgi as seen
by analyzing potential co-localization with the Golgi marker
TGN46 (red signal, Fig. 2B) and nor is it associated with mitochon-
dria marked with Mitotracker (red signal, Fig. 2C). These results
clearly demonstrate that URG7 has a distinct localization within
the cells at the level of the ER.C
- + - +
lane 1) and with pcDNA3/URG7ﬂag (lane 2). (B) URG7 enzymatic deglycosylation.
PNGase F (+/). (C) Tunicamycin treatment. Whole lysate from URG7ﬂag transfected
Arrows 1 and 2 mark the N-glycosylated and the deglycosylated URG7 proteins,
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To further investigate the ER targeting and membrane topology
of URG7, wild-type URG7 (WT) was expressed in the reticulocyte
lysate in vitro system in the absence and presence of pancreatic ca-
nine rough microsomes (CRM). The radioactively labeled protein
products were analyzed by SDS–PAGE (Figs. 3 and 4) and quanti-
ﬁed (Table 1). In the absence of CRM, URG7 WT migrated close to
the 15 kDa marker (Fig. 3A, lane 1), which corresponds well to its
theoretical molecular weight of 10.8 kDa. In the presence of CRM,
about 54% of URG WT was in an endoglycosidase H (Endo H) sen-
sitive fraction (Fig. 3A, lanes 2–4) that migrated about 2.5–3 kDa
above the protein in the absence of CRM. Thus, the only N-linked
glycosylation site possibly modiﬁed in URG7 (N15Q16T17) is glycos-
ylated in vitro to a similar level as found in HepG2 cells. The results
indicate that at least 54% of URG7 expressed in vitro is targeted to
the ER (Fig. 1).
To address whether URG7 is translocated across the ER mem-
brane and forms a soluble lumenal protein or if its predicted trans-
membrane segment is inserted into the ER membrane forming an
integral membrane protein, a set of constructs with engineered
N-linked glycosylation sites were designed. An additional N-linked
glycosylation site with the acceptor asparagine in position 73
(N73) on the C-terminal side of the predicted transmembrane seg-
ment was made and the expressed protein was 9% doubly glycos-
ylated (Fig. 3B), indicating that 9% of URG7 is totally translocated
across the ER membrane. 50% of URG7 N73 was singly glycosyl-
ated, which suggests that the transmembrane segment is insertedA B
Fig. 2. Immunoﬂuorescence analysis of cells expressing URG7. HepG2 cells, transiently
staining with anti-URG7ﬂag (green), anti-calnexin (red, A) and anti-TGN46 (red, B) anti
Fig. 3. SDS–PAGE analysis of the URG7 constructs expressed in vitro. (A) URG7WT, (B) UR
the absence and presence of CRM, and were treated with Endo H or untreated but in the
protein are indicated as open and ﬁlled circles, respectively. The number of ﬁlled circles
background band. The models of the constructs indicate the positions of the N-linked gin the membrane with either the N- or C-terminal tail glycosylated
in the lumen of the ER.
To verify the topology of the ER membrane inserted fraction of
URG7, double glycosylation sites were introduced in either the N-
or C-terminal tail in the constructs URG7 P7A/N8 and URG7 N73/
N85, respectively (Fig. 3C and D). 11% of URG7 P7A/N8 was glycos-
ylated once and 40% twice (Fig. 3C), whichcorresponds to the frac-
tion of the protein product with the N-terminal tail in the lumen of
the ER. In agreement with the above results, the URG7 N73/N85
construct (Fig. 3D) was doubly glycosylated to 18% (URG7 inserted
in the membrane with the C-terminal tail in the lumen) and 46%
singly glycosylated (URG7 inserted in the membrane with the N-
terminal in the lumen). The possible triple glycosylated product
of this construct could not be detected because it would co-migrate
with an Endo H insensitive product.
To increase the signal and the size of the expressed URG7, the
soluble P2 domain of Escherichia coli leader peptidase (Lep) with
one glycosylation site (N97S98T99) was introduced as a fusion pro-
tein at the C-terminus of URG7 (Fig. 4A–C). URG7-P2 displayed
5% doublyglycosylated product and 51% singly glycosylated
(Fig. 4A), which implies that 5% of the whole protein is in the lu-
men and 51% with either N- or C-terminal region in the lumen.
An additional glycosylation site was inserted in the N- (P7A/N8-
P2) and the C- (N73-P2) terminal regions of this construct to deter-
mine the fractions of the protein with a topology that had the
N- and C-terminal region in the lumen, respectively. The URG7
N73-P2 construct displayed 2% triply, 9% doubly and 50% singly
glycosylated product, indicating that 2% is totally translocated,C
transfected with pcDNA3/URG7ﬂag, were assessed for colocalization (yellow) after
bodies as well as MitoTracker (red, C). Planar XY confocal images were depicted.
G7 N73, (C) URG7 P7A/N8 and (D) URG7 N73/N85. The constructs were expressed in
same reaction conditions (Mock). The unglycosylated and glycosylated forms of the
indicates the number of glycosylations. The star is indicating the Endo H insensitive
lycosylation sites (N8, N15, N73 and N85).
Fig. 4. SDS–PAGE analysis of the URG7-P2 and MRP6 (TM1-TM2) constructs expressed in vitro. (A) URG7-P2, (B) URG7 N73-P2, (C) URG7 P7A/N8-P2 and (D) MRP6 (TM1-
TM2). Key as in Fig. 3. The stars indicate cleaved products. The P2 domain of Lep is indicated in light blue.
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the lumen. In good agreement with this, the URG7 P7A/N8-P2 con-
struct exhibited 4% triply, 36% doubly and 10% singly glycosylated
product which implies that 4% is totally translocated, 36% has the
N-terminal and 10% the C-terminal in the lumen.
It should be noted that degradation productswere detected for
the URG7-P2 and URG7 P7A/N8-P2 constructs (Fig. 4A and C) but
not for the URG7 N73-P2 construct, which suggests that the glyco-
sylation in N73 (Fig. 4B) protects the protein from cleavage by sig-
nal peptidase [10].
As a positive control for ER targeting, a construct with the ﬁrst
102 amino acids of MRP6, MRP6 (TM1–TM2), containing the ﬁrst
two predicted transmembrane a-helices (residues 34–56 andTable 1
Quantiﬁcation of the URG7 protein products presented in Figs. 3 and 4. The numbers
are given as percentage of total protein products from at least two independent
experiments. Key as in Figs. 3 and 4.
URG7 constructs Figure s (%)  (%)  (%)  (%) ⁄ (%)
WT 3A 46 54
N73 3B 41 50 9
P7A/N8 3C 49 11 40
N73/N85 3D 36 46 18
–P2 4A 37 51 5 7
N73-P2 4B 39 50 9 2
P7A/N8-P2 4C 42 10 36 4 8
MRP6 (TM1–TM2) 4D 20 8073–92 according to TMHMM) [17], was expressed in the in vitro
system. As for URG7 WT (Fig. 3A), also in this case an Endo H-sen-
sitive product was detected in the presence of CRM (Fig. 4D). For
MRP6 (TM1–TM2) the protein was glycosylated to 80%, indicating
that it is inserted in the ER membrane with the N-terminus in the
lumen.
4. Discussion
We have investigated the cellular localization of URG7 in HepG2
cells and its membrane topology in an in vitro expression system.
The expression of URG7 in HepG2 cells lead to the production of
two distinct protein products of which the one of higher molecular
weight was sensitive to PNGase F treatment and tunicamycin
(Fig. 1). These results indicate that about 35% of URG7 is N-glycos-
ylated in HepG2 cells suggesting that it is at least initially targeted
to the ER. These ﬁndings were corroborated by immunolocalization
experiments showing a co-localization of URG7 with the ER marker
calnexin (Fig. 2A). The fact that URG7 does not enter the Golgi
apparatus (Fig. 2B) or mitochondria (Fig. 2C) strongly supports that
it remains in the ER.
The topology and ER targeting of URG7 was determined by
in vitro expression of URG7 WT and as P2 fusions with engineered
N-linked glycosylation sites (Fig. 3A–D and Fig. 4A–C and Table 1).
These results indicate that 50–64% of URG7 is targeted to the ER as
seen from the percentage of protein glycosylated at least once
3062 A. Ostuni et al. / FEBS Letters 587 (2013) 3058–3062(Fig. 3B and D and Fig. 4A–C). The topological studies of URG7 can
be summarized as follows: 2–9% resides in a soluble form in the lu-
men as indicated by the doubly glycosylated (Fig. 3B and Fig. 4A)
and triply glycosylated products (Fig. 4B and C); 9–18% spans the
membrane with the C-tail facing the lumen as suggested by the
doubly glycosylated product (Fig. 3D and Fig. 4B) and singly glycos-
ylated products (Fig. 4C); 36–50% of URG7 spans the membrane
with the N-tail facing the lumen as shown by the doubly (Fig. 3C
and Fig. 4C) and singly glycosylated products (Fig. 3D and
Fig. 4B). In conclusion, the dominant topology of URG7 expressed
in vitro is the Nlumen–Ccytosol orientation, although it displays minor
topological variations.
MRP6 (TM1–TM2) was also expressed in vitro and it displayed
80% glycosylated product (Fig. 4D) close to the maximum observed
in this system [15,14] corroborating previous reports suggesting
that full-length MRP6 is glycosylated [6]. Thus the MRP6 residues
that differ from URG7 (75–102 of MRP6) improve ER targeting
and insertion, which could be explained by the higher hydropho-
bicity of the second transmembrane segment (DG-value of
0.922 kcal mol1, http://dgpred.cbr.su.se/) found in that region,
compared to the ﬁrst transmembrane segment (DG-value of
0.707 kcal mol1). Another difference is that URG7, unlike MRP6,
is most likely targeted post-translationally to the ER membrane be-
cause its C-tail contains only 43 residues, which is just about en-
ough to span the ribosome tunnel [18,19]. Although MRP6 and
URG7 share targeting signals for the ER, MRP6 has been suggested
to be localized to the plasma membrane or mitochondria-associ-
ated membranes [6,7]. Our results therefore further suggest that
the ER retention signal for URG7 is found among residues 74–99
that are different from those of MRP6.
URG7 has been shown to inhibit TNFa-mediated apoptosis by
blocking caspase 8 and downstream caspase 3 activity. It was
hypothesized that URG7 acts byactivating b-catenin or PI3K/Akt
[3]. According to the localization, targeting and topology analysis
in this study, the majority of the N-terminal 74 residues of URG7,
that are also identical to those of MRP6, either faces the ER lumen
or spans ER membrane. It is therefore unlikely that this protein
portion plays a role in apoptosis. The C-terminal 25 residue region
of URG7 was found to face the cytosol, which makes it a more
likely player interfering with apoptosis. It should be noted that
the residues 82–95 in the C-terminal cytosolic region of URG7 con-
tain a sequence motif that is highly homologous to the extreme C-
terminal residues 269–283 of the human synoviolin isoform CRA_b
(EAW74358.1).
URG7 82 EP-GNV–RGRQGTGWN 95 (99)
EP-G-V–RGRQ–GWN
CRA_b 269 EPLGTVTARGRQ–GWN 283 (285)
Another longer isoform of synoviolin, also known as HRD1, has
been shown to be located to the ER membrane with its C-terminal
domains in the cytoplasm [20], where it sequesters and facilitates
degradation of p53 as a part of an anti-apoptotic mechanism [21].
The CRA_b isoform has not yet been characterized so it is not
known if it plays a role in apoptosis and the homologous sequence
motif found in URG7 and CRA_b is not found in HRD1. However, we
would like to speculate that the C-terminal cytosolic tails of URG7
and CRA_b could be involved in an analogous anti-apoptotic mech-
anism by binding a pro-apoptotic component, anchoring it to the
ER membrane and thereby inhibiting the apoptosis signaling
pathway.
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